2021 韩国胰腺癌临床实践指南:基于证据的多学科诊断和治疗方法总结

2021-10-01 韩国胰腺癌临床实践指南委员会和韩国国家癌症中心 Pancreatology

这是韩国胰腺癌临床实践指南 2021 的英文版。该指南包括 20 个临床问题和 32 个陈述。该指南代表了韩国目前成人胰腺导管腺癌诊断和治疗的最标准指南。作者相信本指南将提供有用且信息丰富的建议。

中文标题:

2021 韩国胰腺癌临床实践指南:基于证据的多学科诊断和治疗方法总结

发布日期:

2021-10-01

简要介绍:

胰腺癌是韩国第八大常见癌症,也是导致癌症相关死亡的第五大常见原因。为了实现管理的标准化并促进结果的改善,韩国共有 53 名胃肠病学、外科、医学肿瘤学、放射肿瘤学、放射学、核医学和病理学的多学科专家提出了新的建议,其中整合了最新的日期、循证研究结果和专家意见。对影像学诊断、内镜治疗、手术、放疗、姑息性化疗和具体管理程序(包括新辅助治疗)提出了建议 或用于可切除、临界可切除和局部晚期不可切除胰腺癌患者的辅助治疗。

这是韩国胰腺癌临床实践指南 2021 的英文版。该指南包括 20 个临床问题和 32 个陈述。该指南代表了韩国目前成人胰腺导管腺癌诊断和治疗的最标准指南。作者相信本指南将提供有用且信息丰富的建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 韩国胰腺癌临床实践指南:基于证据的多学科诊断和治疗方法总结.pdf)] GetToolGuiderByIdResponse(projectId=1, id=bb1c41c00228a1b7, title=2021 韩国胰腺癌临床实践指南:基于证据的多学科诊断和治疗方法总结, enTitle=, guiderFrom=Pancreatology, authorId=0, author=, summary=这是韩国胰腺癌临床实践指南 2021 的英文版。该指南包括 20 个临床问题和 32 个陈述。该指南代表了韩国目前成人胰腺导管腺癌诊断和治疗的最标准指南。作者相信本指南将提供有用且信息丰富的建议。, cover=https://img.medsci.cn/2021125/1638711932919_1608702.png, journalId=0, articlesId=null, associationId=2204, associationName=韩国胰腺癌临床实践指南委员会和韩国国家癌症中心, associationIntro=韩国胰腺癌临床实践指南委员会和韩国国家癌症中心, copyright=0, guiderPublishedTime=Fri Oct 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p id="abspara0010" style="color: #2e2e2e;">胰腺癌是韩国第八大常见癌症,也是导致癌症相关死亡的第五大常见原因。为了实现管理的标准化并促进结果的改善,韩国共有 53 名胃肠病学、外科、医学肿瘤学、放射肿瘤学、放射学、核医学和病理学的多学科专家提出了新的建议,其中整合了最新的日期、循证研究结果和专家意见。对影像学诊断、内镜治疗、手术、放疗、姑息性化疗和具体管理程序(包括新辅助治疗)提出了建议&nbsp;或用于可切除、临界可切除和局部晚期不可切除胰腺癌患者的辅助治疗。</p> <p id="abspara0015" style="color: #2e2e2e;">这是韩国胰腺癌临床实践指南 2021 的英文版。该指南包括 20 个临床问题和 32 个陈述。该指南代表了韩国目前成人胰腺导管腺癌诊断和治疗的最标准指南。作者相信本指南将提供有用且信息丰富的建议。</p>, tagList=[TagDto(tagId=439, tagName=消化道肿瘤), TagDto(tagId=718, tagName=胰腺癌), TagDto(tagId=25496, tagName=胰腺疾病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=718, guiderKeyword=胰腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=5, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3458, appHits=67, showAppHits=0, pcHits=401, showPcHits=3391, likes=0, shares=10, comments=3, approvalStatus=1, publishedTime=Sun Dec 05 21:52:53 CST 2021, publishedTimeString=2021-10-01, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Sun Dec 05 21:50:00 CST 2021, updatedBy=6415643, updatedName=凯晨, updatedTime=Fri Jan 05 20:47:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 韩国胰腺癌临床实践指南:基于证据的多学科诊断和治疗方法总结.pdf)])
2021 韩国胰腺癌临床实践指南:基于证据的多学科诊断和治疗方法总结.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193066, encodeId=f9af119306671, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c706496907, createdName=ms7000000668896288, createdTime=Sun Feb 13 19:57:03 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077323, encodeId=e2c810e7323cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd991718374, createdName=1debd7bdm05(暂无匿称), createdTime=Mon Dec 06 13:03:06 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077222, encodeId=a70f10e72220d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Dec 06 06:58:14 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2022-02-13 ms7000000668896288

    感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193066, encodeId=f9af119306671, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c706496907, createdName=ms7000000668896288, createdTime=Sun Feb 13 19:57:03 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077323, encodeId=e2c810e7323cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd991718374, createdName=1debd7bdm05(暂无匿称), createdTime=Mon Dec 06 13:03:06 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077222, encodeId=a70f10e72220d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Dec 06 06:58:14 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2021-12-06 1debd7bdm05(暂无匿称)

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193066, encodeId=f9af119306671, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c706496907, createdName=ms7000000668896288, createdTime=Sun Feb 13 19:57:03 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077323, encodeId=e2c810e7323cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd991718374, createdName=1debd7bdm05(暂无匿称), createdTime=Mon Dec 06 13:03:06 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077222, encodeId=a70f10e72220d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Mon Dec 06 06:58:14 CST 2021, time=2021-12-06, status=1, ipAttribution=)]
    2021-12-06 微探

    学习学习

    0

拓展阅读

2010ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

胰腺癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

2012 胰腺癌经动脉灌注化疗指南(草案)

中华医学会放射学分会介入学组 · 2012-05-30

2012 ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2013 胰腺癌多学科综合治疗协作组专家共识

中华医学会肿瘤学分会 · 2013-05-01